首页 | 本学科首页   官方微博 | 高级检索  
     

HER2阳性型乳腺癌脑转移的研究进展
引用本文:周 霞,杜向慧,裘国勤. HER2阳性型乳腺癌脑转移的研究进展[J]. 肿瘤防治研究, 2014, 41(6): 680-685. DOI: 10.3971/j.issn.1000-8578.2014.06.038
作者姓名:周 霞  杜向慧  裘国勤
作者单位:310022 杭州,浙江省肿瘤医院胸部肿瘤放射治疗科
基金项目:浙江省医药卫生科技计划资助项目(2011KYB024);浙江省中医药科技计划资助项目(2011ZA013)
摘    要:近年来曲妥珠单抗的广泛应用大大提高了HER2(人表皮生长因子受体 2)过度表达乳腺癌患者的生存率,在全身性控制率提高和生存期延长的同时,脑转移瘤的发病率也有所增加;同时,脑转移是造成HER2阳性型乳腺癌晚期患者死亡的一项越来越重要的具有临床挑战性的因素——常常是在颅外疾病控制良好的情况下。本文将HER2阳性型乳腺癌脑转移的早期检测和预防的价值,靶向治疗的进展及新靶向药物的开发情况加以总结。

关 键 词:人表皮生长因子受体2;乳腺癌  脑转移;血脑屏障;曲妥珠单抗;拉帕替尼  
收稿时间:2014-01-20

Review on Brain Metastases in HER2-positive Breast Cancer Patients
ZHOU Xia,DU Xianghui,QIU Guoqin. Review on Brain Metastases in HER2-positive Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2014, 41(6): 680-685. DOI: 10.3971/j.issn.1000-8578.2014.06.038
Authors:ZHOU Xia  DU Xianghui  QIU Guoqin
Affiliation:Department of Radiation Oncology, Zhejiang Cancer Hospital,Hangzhou 310022,China
Abstract:The widespread use of trastuzumab in recent years has led to a significant improvement in thesurvival of breast cancer patients with overexpressed human epidermal growth factor receptor-2(HER2-positive). However with improved systemic control and prolonged survival, the incidence of brain metastasishas increased. Brain metastasis, often in the setting of well-controlled extracranial disease, is proved to be anincreasingly important and clinically challenging cause of morbidity and mortality in HER2-positive breastcancer patients. In this review, we will discuss the targeted therapies of HER2-positive brain metastasis andsummarize information about ongoing clinical trials of novel therapies as well as emerging strategies for earlydetection and prevention.
Keywords:HER2  Breast cancer  Brain metastases  Blood-brain barrier  Trastuzumab  Lapatinib  
点击此处可从《肿瘤防治研究》浏览原始摘要信息
点击此处可从《肿瘤防治研究》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号